Quick Answer
RenovoRx, Inc. reported Net Income Loss of -$11.17 million for the year ending 2025.
- RenovoRx, Inc. showed a decrease of -26.7% in Net Income Loss from 2024 to 2025.
- This data is from RenovoRx, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), RenovoRx, Inc.'s Net Income Loss has declined by 194.0%.
- Historical annual values: Fiscal year 2025: -$11.17 million | Fiscal year 2024: -$8.81 million | Fiscal year 2023: -$10.23 million | Fiscal year 2022: -$9.89 million | Fiscal year 2021: -$6.32 million | Fiscal year 2020: -$3.80 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: